Viking Therapeutics Inc (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that develops drug candidates for metabolic and endocrine disorders. The company generates no product revenue, funding operations through equity financings and capital markets rather than product sales or royalties. The 10-K filed 2026-02-11 (accession 000119312526046876) identifies Viking as a well-known seasoned issuer listed on the Nasdaq Capital Market, with shares outstanding as of January 31, 2026. The filing confirms active clinical trials and preclinical studies across its pipeline, with the company explicitly disclosing dependence on additional financing to fund research and development activities. Viking has not yet advanced any drug candidate to commercial approval, placing it in the pre-revenue stage of pharmaceutical development.

Revenue model

The filing excerpts do not disclose a product revenue model. Viking Therapeutics funds operations through capital raises. No licensing, royalty, or product sales revenue is described in the provided excerpts.

Products and services

The filing references drug candidates in clinical trials and preclinical studies targeting metabolic and endocrine disorders. No specific product names, pipeline asset names, or approval status details are supported by the provided filing excerpts.

Customers and end markets

The filing excerpts reference potential patient populations for drug candidates if approved for commercial use, and mention metabolic and endocrine disorder indications. No commercial customers are disclosed, as the company is pre-revenue.

Value-chain role

Clinical-stage drug developer. Conducts clinical trials and preclinical studies internally. No commercial manufacturing or distribution operations are described in the provided excerpts.

Geographic exposure

The filing excerpts do not specify geographic operating markets beyond U.S. SEC registration and Nasdaq Capital Market listing.

Source: SEC 10-K, filed 2026-02-11

Industry: Pharmaceutical Preparations Peers: Lineage Cell Therapeutics Inc Compass Therapeutics Inc. Gritstone bio, Inc. Kronos Bio, Inc. MacroGenics Inc Rigel Pharmaceuticals Inc Shuttle Pharmaceuticals Holdings Inc Xoma Royalty Corp